Health and Medical News and Resources

General interest items edited by Janice Flahiff

[Reblog] Pitfalls of retrospective database studies

 

 

Enhanced by Zemanta

Health Services Authors

As you know a part of my work consists to participate in studies based on the extraction from retrospective databases and the analysis of the informations thus retrieved. The eligibility of the beneficiaries to the provision that represents the study’s outcome is always a major concern. There is two explanations for a beneficiary not having access to a care according to the data retrieved from the reimbursement base: either a real lack of access or a non eligibility of the care for a record in the reimbursement data base (for example if the insured is covered by another insurance or has lost his coverage and has exited from the health plan)*. I have always to keep in mind that I work on secondary data which are only a reflection of the primary data the reality of which I try to apprehend.
The dilemma is pretty well addressed in this article:

View original post 225 more words

March 31, 2014 Posted by | Medical and Health Research News | , | Leave a comment

Early Benefit Assessment for Pharmaceuticals in Germany: Lessons for Policymakers

From the overview (abstract) at the 16 October 2013 Commonwealth Fund posting

Since 2011, Germany’s Pharmaceutical Market Restructuring Act has mandated that all newly introduced drugs are subject to an assessment of their benefits in relation to a comparator, typically the current standard treatment. For drugs found to have some additional benefit, the manufacturer and the statutory health insurers negotiate a price. For drugs found to have no additional benefit, their price is set in reference to the price of the comparator. This new system is intended to reduce spending on expensive new drugs that are no more effective than existing treatments, while encouraging pharmaceutical companies to invest in innovative drugs that improve health outcomes. The German experience provides lessons for the United States, where comparative effectiveness research is publicly funded but public insurance programs are limited in their ability to use its findings to make coverage or pricing decisions.

Screen Shot 2013-10-22 at 5.39.14 AM

Screen Shot 2013-10-22 at 5.41.22 AM

October 22, 2013 Posted by | health care | , , , | Leave a comment

   

%d bloggers like this: